Collective Actions and Proprietary Rights | Part 1
Part 1: The symposium focuses on cases where proprietary rights on research inputs are posing, or may imminently pose, obstacles to biopharmaceutical R & D. Many of these cases involve diseases that have limited market potential, either because the affected population is poor or because it is small. Hence the need to reduce costs related to licensing, as well as other R & D costs, is particularly acute. These concerns may especially affect genomic innovation, where the ability to "invent around" building blocks of knowledge may be limited. Sponsored by the Center for the Study of the Public Domain and the Center for Genome, Ethics, Law and Policy.
Recorded on March 04, 2005.
Conference title: Collective Actions and Proprietary Rights 2005 : Duke University. School of Law).
Appearing: Speakers: Part 1: Moderated by Arti Rai ; Panelists: Amy Kapczynski (Fellow, Yale Law School and Yale School fo Public Health), Yochai Benkler (Professor, Yale Law School), Steven Ferguson (Director, Division of Technology Development and Transfer (NIH Office of Technology Transfer), and Katherine Woo (Director, Scientific Affairs (Institute for OneWorld Health) ; Part 2: Moderated by Anthony So ; Panelists: Alan Bennett (Associate Vice Chancelor, Office of Research (U.C. Davis)), Willard Tom (Director, Scientific Affairs (Partner, Morgan, Lewis & Bockus, LLP), Sandra Shotwell (Managing Partner, Alta Biomedical Group, LLC), Wei Zhou (Senior Director, Legal Attymetrix), and David Martin (President & CEO, M-CAM, Inc.),